Predictive Oncology Inc Stock Price, News & Analysis

Predictive Oncology (NASDAQ: POAI) has announced a strategic collaboration with Every Cure, a nonprofit organization, to accelerate drug repurposing for cancer treatment. The partnership leverages POAI's extensive biobank of 150,000+ tumor samples across 130+ cancer types and AI-driven platform that can screen drugs against various tumor types.

Every Cure will utilize POAI's data from testing approximately 150 FDA-approved drugs on patient tumor samples. The nonprofit employs AI models, including knowledge graphs and large language models, to identify potential connections between existing drugs and diseases. The collaboration aims to expedite the discovery of new cancer treatment options while making healthcare more accessible and economically feasible.

Predictive Oncology (Nasdaq: POAI) reported Q2 2025 financial results, posting a $2.0 million loss from continuing operations. The company's revenue decreased to $2,682 from $67,255 in Q2 2024. Key developments include advancing preparations for ChemoFx® market expansion in the U.S. and Europe, developing two 3D liver toxicity models for Labcorp, and identifying three repurposed drug candidates for colon and breast cancer indications.

The company ended Q2 2025 with $506,078 in cash, down from $611,822 in December 2024. POAI secured a $10 million standby equity purchase agreement with Yorkville Advisors and raised approximately $586,000 through a private placement and ATM facility during the quarter.

Predictive Oncology (NASDAQ: POAI) has secured a $10 million Securities Purchase Agreement with Yorkville Advisors Global to support its growth initiatives. The company is expanding the availability of its ChemoFx® proprietary live-cell tumor profiling assay in the U.S. and launching in Europe.

ChemoFx leverages the company's database of 150,000 tumor samples across 137 cancer types to predict chemotherapy responses, helping oncologists make better treatment decisions. The company plans to extend beyond gynecological cancers into breast, colon, and lung cancers. Additionally, POAI is advancing its AI-driven drug discovery initiatives, including successful development of machine learning models for ovarian cancer outcomes in collaboration with UPMC Magee-Womens Hospital.

Predictive Oncology (NASDAQ: POAI) has secured a $10 million Standby Equity Purchase Agreement (SEPA) with Yorkville Advisors Global's investment fund. The agreement provides flexible funding access to advance the company's AI-driven drug discovery and repurposing initiatives.

Under the SEPA terms, POAI maintains full control over the timing and amount of stock sales, with no warrants, derivatives, or minimum commitments required. The funding will support ongoing drug discovery, biomarker research, and business development opportunities with biopharmaceutical companies through their AI and machine learning capabilities.

Predictive Oncology (NASDAQ: POAI) has developed exclusive 3D liver toxicity organoid models for Labcorp (NYSE: LH), including human and rat variants, to enhance drug discovery and toxicity testing. These models simulate liver microenvironments to predict drug clearance, transport, and hepatotoxicity. The technology leverages POAI's extensive biobank of 150,000+ frozen tumor samples and complements their AI-driven 2D platform and 3D spheroids. The models demonstrated optimal liver morphology and function through various tests, including cell junction formation and hepatotoxicity measurements. This development aligns with the growing organoid-based platform market, which aims to accelerate drug development while reducing reliance on animal testing.

The Delaware Court of Chancery has denied Renovaro's (RENB) request for an expedited trial in July against Predictive Oncology (NASDAQ: POAI), citing RENB's delay in filing their action. The Court has instead scheduled the trial for November 12-13, 2025. POAI, an AI-driven drug discovery company, strongly maintains that RENB's claims are based on inaccurate allegations and lack merit. The company has expressed its commitment to defending its rights and looks forward to presenting its case in court.

Predictive Oncology (NASDAQ: POAI) has announced significant progress in AI-enabled cancer drug discovery, leveraging its extensive biobank of over 150,000 live cell tumor samples across 137 cancer indications. The company successfully developed predictive tumor response models for 21 previously untested molecules from the University of Michigan, targeting common cancers including breast, colon, and ovarian cancers.

This announcement coincides with Regeneron's $256 million acquisition of 23andMe, highlighting the industry's shift toward data-driven drug discovery. The company's proprietary active machine learning platform enables in silico drug response testing before in vitro confirmation, significantly accelerating development timelines and improving the Probability of Technical Success in drug development.

Predictive Oncology (NASDAQ: POAI) has shared significant progress in its AI-driven drug discovery and biomarker development initiatives. The company has achieved key milestones including: successful development of AI-powered survival prediction models for ovarian cancer in collaboration with UPMC Magee-Womens Hospital, identification of novel cancer biomarkers, and expansion of their ChemoFx® assay into Europe. The company leverages its biobank of 150,000 tumor samples across 137 cancer types to validate AI drug response predictions. Operating in the biomarker discovery market, valued at $14.5 billion in 2024 with projected 19.4% CAGR through 2030, POAI is exploring strategic partnerships and advancing drug repurposing initiatives, having identified three promising candidates for ovarian and colon cancer treatment.

Predictive Oncology (NASDAQ: POAI) reported Q1 2025 financial results with a net loss of $2.3 million on revenue of $110,310. Key developments include identifying three repurposed drug candidates (Afuresertib, Alisertib, Entinosta) for breast and colon cancer through AI/ML analysis, launching ChemoFx® drug response assay in Europe, and selling Skyline Medical assets to DeRoyal Industries. The company ended Q1 with $3.1 million in cash, up from $611,822 in December 2024. Operating expenses decreased across all categories, with G&A expenses down to $1.8 million from $2.3 million YoY. Loss per share improved to $0.32 compared to $0.88 in Q1 2024, while revenue increased significantly from $4,858 in Q1 2024.